Safety and feasibility of intradermal injection with tolerogenic dendritic cells pulsed with proinsulin peptide-for type 1 diabetes

Lancet Diabetes Endocrinol. 2020 Jun;8(6):470-472. doi: 10.1016/S2213-8587(20)30104-2. Epub 2020 May 5.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Controlled Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autoimmunity / immunology
  • Dendritic Cells / immunology*
  • Diabetes Mellitus, Type 1 / immunology
  • Diabetes Mellitus, Type 1 / therapy*
  • Erythema / etiology
  • Feasibility Studies
  • Humans
  • Immune Tolerance*
  • Immunotherapy / adverse effects
  • Immunotherapy / methods*
  • Injections, Intradermal
  • Insulin-Secreting Cells / immunology
  • Insulin-Secreting Cells / physiology
  • Leukapheresis
  • Placebos
  • Proinsulin / administration & dosage*
  • Prospective Studies

Substances

  • Placebos
  • Proinsulin